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We have recently described a series of human fetal cloned cell lines that express CD3 proteins but not the a/# T cell receptor (TCR) (1) . One of these clones, termed F6C7, was used for mice immunizations. An mAb, designated anti-NKFi was found to identify on F6C7 lymphocytes a CD3-associated y chain (2, 3) expressed either as a homodimer or possibly as part of an heterodimer (note that a S chain has remained undetected on F6C7 cells) . Anti-NKFi was shown to have a highly restricted clonotypic reactivity and could not therefore be used for characterization of lymphocyte subpopulations with a TCR-y complex. Here, we describe a novel mAb, anti-Ti-yA, which immunoprecipitates the same y protein as anti-NKFi . However, the Ti-yA determinant corresponds to a public epitope of this molecule, the expression of which delineates a unique subset accounting for^-3% of human circulating lymphocytes.
Materials and Methods
mAbs and Immunofuorescence Analyses. Anti-Ti-yA was produced in mice after immunization with a CD3+, WT31 -cloned cell line derived from peripheral blood of a healthy adult individual . Cell fusions were performed according to a standard method described previously (2) . Anti-Ti-yA is of the IgG2a subclass . BMA 031 mAb was kindly provided by Dr . Kurrle from the Behring Co . (Marburg, Federal Republic of Germany) . This reagent recognizes a monomorphic determinant of the Ti a/# receptor (4) . All other antibodies used in this study have been extensively characterized. Immunofluorescence (IF) experiments were performed on freshly drawn peripheral blood from healthy adult individuals . Nonadherent cells were treated for 30 min with either fluoresceinated antiTi-yA alone or anti-Ti-yA plus, individually, anti-CD2, -CD3, -CD4, -CD5, -CD6, -NKH 1, -Ia mAb coupled to phycoerythrin (PE), kindly provided by the Coultronics Co. (Margency, France). For the comparative analysis of anti-Ti-yA reactivity in peripheral blood, we used OKT3 (Ortho Pharmaceuticals, Raritan, NJ) and BMA 031 (Behring Co .) . 3 .0 x 10' cells were analyzed in each sample on an Epics C instrument (Coulter Electronics, Inc., Hialeah, FL). Control reagents were FITC-IgG and PE-IgG .
Immunoprecipitations. F6C7 cells were surface labeled with '25 1 using a standard lactoperoxidase method (2) . After several steps of preclearing with Staphylococcus A suspension as well as irrelevant antibodies, specific precipitations were carried out for 6 h at 4°C with either anti-NKFi or anti-Ti-yA coupled to protein A-Sepharose beads. Samples were then retreated twice, for 4 h, with the same antibodies before overnight precipitation with the reciprocal mAb. SDS-PAGE was performed using 9% polyacrylamide gels either under nonreducing conditions or under reducing conditions after addition of 5% 2-ME .
Results and Discussion Anti-Ti-yA Recognizes the Same Molecule as Anti-NKFi. Mice were immunized with a CD3+, WT31 -, NIKE-, clone derived from peripheral blood of an adult donor . Among a large series of hybridoma supernatants, one reacted with the previously described F6C7 cells (1-3) and not with a conventional cloned T lymphocyte expressing an a/,B heterodimer. The mAb secreted by this hybridoma, termed anti-Ti-yA, recognized an antigenic determinant comodulating with CD3 and NKFi on the surface of F6C7 lymphocytes (not shown) . Thus, experiments were performed to compare the molecules immunoprecipitated from F6C7 cells by anti-Ti-yA and anti-NKFi. As previously reported, NKFi resolved in SDS-PAGE analysis as one 85 kD band under nonreducing conditions ( Fig. 1 a) and as two bands at 44 and 41 kD under reducing conditions ( Fig . 1 e) . The anti-Ti-yA-precipitated material showed a virtually superimposable electrophoretic mobility (Fig . 1, b and f) . Sequential precipitations confirmed the identity between NKFi and Ti-7A molecules because there was no material further recognized by anti-NKFi when samples were precleared with anti-Ti--YA ( Fig. 1 c, nonreduced ; lane g, reduced) and reciprocally (lane d, nonreduced; lane h, reduced) . Because it was previously shown (3) that both the 44 and 41 kD NKFi bands are bound by a rabbit heteroantiserum specific for a 20-amino-acid peptide encoded by the first exon of the C71 gene, we concluded here that antiTi-yA recognizes a TCR y chain complex .
Anti-Ti-yA Defines a Subset ofPeripheral Blood Lymphocytes . We tested anti-Ti-7A reactivity against a series of seven CD3'} , WT31 -, NKFi-cloned cell lines derived from peripheral blood of several adult donors . Five out of seven were found to be Ti-yA' . Given this relatively broad distribution, it was possible that anti-Ti-yA would define a detectable subpopulation of peripheral blood lymphocytes . Analysis of 30 individuals revealed that^-3% of lymphocytes are Ti-yA', with major differences from one donor to another ranging from <1 to 15% (data not shown) .
Experiments that led to the discovery of y proteins have been based on the observation that certain normal cloned fetal lymphocytes (1) as well as thymocytes (5) or lymphocytes derived from immunodeficient patients (6) reacted with anti-CD3 mAbs but not with anti-WT31, an mAb that recognizes a monomorphic determinant of Ti-a/# (7). It was shown that at least a fraction of these CD3+ Ti-a/(#-cells surface-express polypeptides (3, 5, 6, (8) (9) (10) ) encoded by T cell rearranging y genes (for review, see reference 11). Such findings supported the view that a given T cell would carry either an a/(l, or alternatively, a 'r receptor complex . Normal peripheral lymphocytes were therefore tested by two-color immunofluorescence analysis with fluoresceinated anti-Ti-7A plus biotinylated BMA-031, revealed by avidin-PE. In all five-donors tested, no double-labelled cells were detected, demonstrating that expression of TCR a/,Q and Ti--YA structures is mutually exclusive on peripheral lymphocytes (histograms from three distinct donors are shown in Fig. 2A ). We then studied the relationship between the Ti-yA population and the well-characterized lymphocyte subsets defined by individual expression of CD2, CD3, CD4, CD5, CD8, NKH1, and MHC class II gene products . 10 healthy adults were tested. Two of them had only 1 % of Ti-yA+ lymphocytes, which made a quantitative analysis of doublefluorescent cells rather inaccurate, in particular with second antibodies delineating additional minor subsets such as anti-CD8 or anti-NKH 1 ; they have not been included in Table I , which summarizes the results obtained with the remaining eight individuals, for whom the average anti-Ti-7A reactivity measured on the lymphocyte population was 6%, ranging from 3 to 15% .
>94% of Ti-yA+ cells expressed CD2 in all donors but one (Table 1 ). In this latter individual only a minority of Ti-7A+ lymphocytes reacted with Coulter clone CD2. Further studies will have to elucidate the significance of this observation . In seven donors, CD3 proteins were present on >95% of Ti-yA+ lymphocytes . In one case, anti-CD3 reacted with 92% of Ti-7A'' cells. This probably reflects a technical artifact such as, for example, partial antibody release rather Table I than a true surface expression of y chains without CD3 proteins . Virtually all CD4+ lymphocytes were found to be Ti-yA-. There always was a small minority of Ti-yA+ cells unreactive with anti-CD5 . Moreover, as opposed to CD2 and CD3 (Fig. 2B) , expression of CD5 was weak on Ti-,yA+ cells. Analysis with anti-CD8 led to the most heterogeneous results. For example, two individuals had <20% of CD8'' cells in their Ti-yA' population, while in one donor, a majority of Ti-yA+ cells were CD8' (Table 1) . CD8 density was always weak on Ti-,yA+ cells (see Fig. 2 C, which shows representative histograms obtained with three distinct normal individuals) . Thus, an accurate delineation of at least one subset of peripheral lymphocytes expressing Ti-,y chains cannot be based on the lack of expression of both CD4 and CD8 proteins. Anti-NKH 1 (12) was found not to react with most Ti-yA + lymphocytes . When some reactivity was detected, it was weaker than that observed on CD3 -NK cells. Finally, most Ti-yA' cells were found not to express class 11 MHC gene products, supporting the view that these lymphocytes are in a resting state.
Because a minority of CD3+, WT31 -clones that we have derived from peripheral blood are Ti-7A-, it is most likely that the corresponding antibody does not detect all circulating lymphocytes with y receptors . We have tried here to delineate the fraction of TCR y+ cells, which are recognized by anti-Ti-7A assuming, as a working hypothesis, that all CD3+ TCR-a/# -lymphocytes express at least one y protein . For this purpose, we used the OKT3 mAb to detect cells expressing CD3 proteins and the BMA-031 mAb to detect cells expressing an a/,8 receptor . In the lymphocyte fraction isolated from an additional series of nine healthy donors, there were 6% (range, 1-12%) more OKT3+ than BMA-031' cells, while the mean reactivity of anti-Ti-yA was 4% (range, 1-10%).
Further studies will have to elucidate the relationship between this predominant subpopulation of TCR-y+ lymphocytes and the remaining CD3+ TCR-a/,0-Ti-yA-cells. In this regard, it should be of particular interest to identify the gene coding for the Ti-7A epitope (most likely, it is neither a C-yl or a C-y2 segment, because our CD3+ TCR-a/#-Ti-yA -clones express disulfide-linked dimers as well as CD3+ Ti-yA+ cells) . Furthermore, anti-Ti-yA mAb may help to study potential structural differences between CD3-associated 'Y complexes, which appear to include, in many cases, at least one additional still poorly characterized protein designated S (or X) (6, (8) (9) (10) 13) . Finally, the delineation of this novel subset should allow us to better characterize the biological role of TCR-y+ cells, and to determine whether protein products of T cell y rearranging genes are involved as receptors directing functional activities such as, for example, non-MHC-restricted killing.
Summary
We have previously characterized a CD3 + T cell receptor (TCR) a/#-human fetal cloned cell line, termed F6C7, which surface-expresses a CD3-associated y chain identified by anti-NKFi, an mAb with a restricted clonotypic reactivity. Here, we have produced an additional antibody, anti-Ti-yA, which recognizes a public epitope of the y molecule defined by anti-NKFi . Ti-yA is present on -r3% ofcirculating lymphocytes with a wide range (1-15%) among 30 healthy individuals tested . Two-color immunofluorescence experiments performed with antiTi-yA and BMA 031 mAb (a reagent specific for the TCR-a/,B receptor) showed that surface expression of Ti-a/fl and Ti-yA is mutually exclusive . Moreover, it was found that most Ti-yA+ cells are CD2+, CD3+, CD4 -, CD5+, NKH1 -, HLA class II-negative . In contrast, the expression of the CD8 molecule on these T lymphocytes appears to be variable from one individual to another. Finally, we found that Ti-yA + cells represent a majority of peripheral lymphocytes that express CD3 proteins but not the TCR-a/,# heterodimer. The delineation of this unique lymphocyte subset should help further studies on the biology of cells with a CD3-associated y complex .
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